- PR Newswire•10 hours agoAcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 in the Emergency Department at the International Society for Burn Injuries
REDWOOD CITY, Calif., Aug. 29, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that the Company and its investigators will be presenting results from the Phase 3 SAP302 ...
- Benzinga•14 days ago
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) disclosed top line results of its ARX-04 final stage study, which met its primary endpoint. The specialty pharmaceutical company indicated 76 adults were given ...
- PR Newswire•14 days agoAcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced Pain Intensity in ER Patients with Moderate-to-Severe Acute Pain
REDWOOD CITY, Calif., Aug. 15, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
AcelRx Pharmaceuticals, Inc. (ACRX)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Bid||3.10 x 1000|
|Ask||3.40 x 500|
|Day's Range||3.23 - 3.30|
|52wk Range||2.40 - 5.88|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-5.34|
|Avg Vol (3m)||357,612|
|Dividend & Yield||N/A (N/A)|